Stressgen's Genital Warts Program Ahead of Schedule Due to Early Completion of Patient Enrollment in Phase II Trial

First Genital Warts Data to be Presented in June 2001



Apr 10, 2001, 01:00 ET from Stressgen Biotechnologies Corp.

    VICTORIA, BC, April 10 /PRNewswire/ - Stressgen Biotechnologies
 Corporation (TSE: SSB) announced today that patient enrollment in its Phase II
 clinical trial investigating HspE7 as a novel immuno-therapeutic for genital
 warts caused by human papillomavirus (HPV) has been completed ahead of
 schedule. There are 5.5 million new cases of genital HPV infection diagnosed
 per year in the U.S. alone, of which approximately one million represent new
 cases of genital warts.
     This randomized double-blind placebo-controlled study initiated in
 January 2001 saw rapid enrollment of the protocol-required 52 patients at
 multiple study centers in the United States. Data from this trial will be
 analyzed in the fourth quarter of 2001. Effectiveness of HspE7 will be
 assessed as regression of warts by standardized clinical criteria. These data
 will then be submitted to an appropriate scientific conference for public
 presentation.
     "We are pleased with the rapid enrollment for our genital warts clinical
 trial, and the steady progress made in the HspE7 clinical program," said
 Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen.
 "Together with the recent announcement of orphan drug status for HspE7 for the
 treatment of recurrent respiratory papillomatosis (RRP), a serious HPV-related
 disease, these developments help us to evaluate the full potential for HspE7
 as a crucial therapeutic solution to major public health issues." RRP is
 caused by the same HPV types that cause genital warts.
     In June 2001, retrospective data on genital warts will be presented at
 the American Society of Colon and Rectal Surgeon's Annual Meeting. These
 clinical observations were made during Stressgen's Phase II trial in anal
 dysplasia where a number of patients had concomitant genital warts.
     Stressgen is evaluating the potential of HspE7 as a broad based
 therapeutic for diseases caused by human papillomavirus (HPV). The Company
 currently has a number of clinical trials ongoing, including one Phase III
 trial, and several Phase II trials, and will soon initiate a clinical trial to
 evaluate HspE7 for recurrent respiratory papillomatosis.
     HspE7, a recombinant fusion product created with Stressgen's proprietary
 Hsp fusion technology, is composed of heat shock protein 65 (Hsp65) from
 Mycobacterium bovis BCG and the protein E7. As a member of the family of
 stress proteins, Hsp65 is known to elicit a powerful immune response. The E7
 protein is derived from HPV and is involved in the malignant transformation of
 epithelial cells. E7 is a tumor-specific antigen and represents a precise
 target for the immune system attack on infected cells.
 
     Stressgen is a public biopharmaceutical company focused on the
 development and commercialization of innovative stress protein-based
 immunotherapeutics. The Company is developing a broad range of products for
 the treatment of viral infections and related cancers. In addition to
 targeting HspE7 in HPV-related diseases, the Company has also initiated
 research studies to evaluate its Hsp technology in the treatment of asthma,
 allergy and hepatitis. Stressgen is an internationally recognized supplier of
 research products for the study of cellular stress, apoptosis, oxidative
 stress and neurobiology, which are used by scientists worldwide.
 
     This news release contains certain forward-looking statements that
 involve risks and uncertainties. Such forward-looking statements include
 statements regarding the efficacy and intended utilization of HspE7 in genital
 warts, the Company's clinical trials and its ability to develop therapeutics.
 Such statements are only predictions. Factors that may cause the ultimate
 results or our performance to be materially different from those implied by
 such statements include risks that products that appeared promising in early
 research do not demonstrate safety or efficacy in larger-scale clinical
 trials, that the Company will not obtain approval to market its products, and
 that progress from research to commercialization will be difficult. These
 factors and others are more fully discussed in our Annual Report on Form 10-K
 and other filings with the Securities and Exchange Commission. The Company
 does not assume any obligation to update or alter the contents of this news
 release.
 
 

SOURCE Stressgen Biotechnologies Corp.
    VICTORIA, BC, April 10 /PRNewswire/ - Stressgen Biotechnologies
 Corporation (TSE: SSB) announced today that patient enrollment in its Phase II
 clinical trial investigating HspE7 as a novel immuno-therapeutic for genital
 warts caused by human papillomavirus (HPV) has been completed ahead of
 schedule. There are 5.5 million new cases of genital HPV infection diagnosed
 per year in the U.S. alone, of which approximately one million represent new
 cases of genital warts.
     This randomized double-blind placebo-controlled study initiated in
 January 2001 saw rapid enrollment of the protocol-required 52 patients at
 multiple study centers in the United States. Data from this trial will be
 analyzed in the fourth quarter of 2001. Effectiveness of HspE7 will be
 assessed as regression of warts by standardized clinical criteria. These data
 will then be submitted to an appropriate scientific conference for public
 presentation.
     "We are pleased with the rapid enrollment for our genital warts clinical
 trial, and the steady progress made in the HspE7 clinical program," said
 Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen.
 "Together with the recent announcement of orphan drug status for HspE7 for the
 treatment of recurrent respiratory papillomatosis (RRP), a serious HPV-related
 disease, these developments help us to evaluate the full potential for HspE7
 as a crucial therapeutic solution to major public health issues." RRP is
 caused by the same HPV types that cause genital warts.
     In June 2001, retrospective data on genital warts will be presented at
 the American Society of Colon and Rectal Surgeon's Annual Meeting. These
 clinical observations were made during Stressgen's Phase II trial in anal
 dysplasia where a number of patients had concomitant genital warts.
     Stressgen is evaluating the potential of HspE7 as a broad based
 therapeutic for diseases caused by human papillomavirus (HPV). The Company
 currently has a number of clinical trials ongoing, including one Phase III
 trial, and several Phase II trials, and will soon initiate a clinical trial to
 evaluate HspE7 for recurrent respiratory papillomatosis.
     HspE7, a recombinant fusion product created with Stressgen's proprietary
 Hsp fusion technology, is composed of heat shock protein 65 (Hsp65) from
 Mycobacterium bovis BCG and the protein E7. As a member of the family of
 stress proteins, Hsp65 is known to elicit a powerful immune response. The E7
 protein is derived from HPV and is involved in the malignant transformation of
 epithelial cells. E7 is a tumor-specific antigen and represents a precise
 target for the immune system attack on infected cells.
 
     Stressgen is a public biopharmaceutical company focused on the
 development and commercialization of innovative stress protein-based
 immunotherapeutics. The Company is developing a broad range of products for
 the treatment of viral infections and related cancers. In addition to
 targeting HspE7 in HPV-related diseases, the Company has also initiated
 research studies to evaluate its Hsp technology in the treatment of asthma,
 allergy and hepatitis. Stressgen is an internationally recognized supplier of
 research products for the study of cellular stress, apoptosis, oxidative
 stress and neurobiology, which are used by scientists worldwide.
 
     This news release contains certain forward-looking statements that
 involve risks and uncertainties. Such forward-looking statements include
 statements regarding the efficacy and intended utilization of HspE7 in genital
 warts, the Company's clinical trials and its ability to develop therapeutics.
 Such statements are only predictions. Factors that may cause the ultimate
 results or our performance to be materially different from those implied by
 such statements include risks that products that appeared promising in early
 research do not demonstrate safety or efficacy in larger-scale clinical
 trials, that the Company will not obtain approval to market its products, and
 that progress from research to commercialization will be difficult. These
 factors and others are more fully discussed in our Annual Report on Form 10-K
 and other filings with the Securities and Exchange Commission. The Company
 does not assume any obligation to update or alter the contents of this news
 release.
 
 SOURCE Stressgen Biotechnologies Corp.